Atara Biotherapeutics Inc (ATRA) CFO John Mcgrath Sells 37,000 Shares

Atara Biotherapeutics Inc (NASDAQ:ATRA) CFO John Mcgrath sold 37,000 shares of the firm’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $24.35, for a total value of $900,950.00. Following the sale, the chief financial officer now directly owns 93,154 shares in the company, valued at approximately $2,268,299.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

John Mcgrath also recently made the following trade(s):

  • On Saturday, December 29th, John Mcgrath sold 32,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $20.00, for a total value of $640,000.00.
  • On Friday, December 29th, John Mcgrath sold 32,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $20.00, for a total value of $640,000.00.

Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) opened at $28.25 on Friday. Atara Biotherapeutics Inc has a 1 year low of $11.80 and a 1 year high of $30.40.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). sell-side analysts expect that Atara Biotherapeutics Inc will post -4 EPS for the current fiscal year.

A number of equities research analysts have recently commented on the company. BidaskClub raised Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price on the stock in a research report on Wednesday, January 3rd. ValuEngine raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Thursday, November 9th. Finally, Jefferies Group reissued a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, October 5th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Atara Biotherapeutics presently has an average rating of “Buy” and an average price target of $26.00.

A number of institutional investors have recently made changes to their positions in ATRA. SG Americas Securities LLC acquired a new stake in Atara Biotherapeutics in the 3rd quarter valued at approximately $142,000. Voya Investment Management LLC raised its position in Atara Biotherapeutics by 16.2% in the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 1,651 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Atara Biotherapeutics in the 3rd quarter valued at approximately $170,000. State of Wisconsin Investment Board acquired a new stake in Atara Biotherapeutics in the 2nd quarter valued at approximately $252,000. Finally, The Manufacturers Life Insurance Company grew its stake in Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 1,369 shares in the last quarter. 85.61% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Atara Biotherapeutics Inc (ATRA) CFO John Mcgrath Sells 37,000 Shares” was published by Stock Observer and is the property of of Stock Observer. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.thestockobserver.com/2018/01/14/atara-biotherapeutics-inc-atra-cfo-john-mcgrath-sells-37000-shares.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply